LCT buoyed by 'stunning progress' in human trials

[ Follow-Ups ] [ Post Followup ] [ The Islet Foundation Public Message Forum ]

Posted by National Business Review on 22:08:13 2009/06/16

Your browser does not support inline frames, or it has been configured incorrectly. If page does not display on your browser, please <a href="http://www.nbr.co.nz/article/living-cell-buoyed-diabetes-trials-103824">CLICK HERE</a>. Living Cell buoyed by diabetes trials | The National Business Review - New Zealand - business, markets, finance, politics, property, technology and more @import "/files/css/ccc73ec3df3d33320ba8182016f3ad0d.css"; Drupal.extend({ settings: { "quicktabs": { "effect": "none" }, "googleanalytics": { "trackDownload": "pdf|zip|mp3", "LegacyVersion": 0 } } }); Sign up for NBR's Daily News Emails $(document).ready(function(){ var defaultname = 'Name'; var defaultemail = 'Email'; //$('#form-subscribe') $('#subname').val(defaultname); $('#subemail').val(defaultemail); $('#subname').bind('focus', function() { if($('#subname').val() == defaultname) $('#subname').val(''); }); $('#subname').bind('blur', function() { if($('#subname').val() == '') $('#subname').val(defaultname); }); $('#subemail').bind('focus', function() { if($('#subemail').val() == defaultemail) $('#subemail').val(''); }); $('#subemail').bind('blur', function() { if($('#subemail').val() == '') $('#subemail').val(defaultemail); }); $('#form-subscribe').bind('submit', function() { if($('#subname').val() == defaultname) $('#subname').val('') if($('#subemail').val() == defaultemail) $('#subemail').val('') }); }); hidden text Midday Edition: 2:08PM Wednesday 17 June 2009 Contact Advertise Subscribe to print edition Email alerts Font size Home Business Markets Politics Tech Property Opinion Ad/Media Well-being Private Bin Search What happens in Jerusalem or Tehran really does matter, eventually, to how investors fare in Auckland or Sydney. this is not a blog post David Cohen Most Popular Read Emailed Commented on Shared Rising costs putting pressure on health insurance premiums Hollywood to NZ govt: stick to your guns on terminating pirates Dealing the gay card Wall Street stocks continue to slide as oil price drops again You can check out, but you can never leave PRIVATE BIN: All Blacks choose euros over US dollars in Adidas deal Rising costs putting pressure on health insurance premiums The strange timeline of the Neelam Choudary allegations 7 reasons to love iPhone OS 3.0 Hollywood to NZ govt: stick to your guns on terminating pirates Top politicians won't vote on smacking Rising costs putting pressure on health insurance premiums Two million-strong revolt sees Facebook cave on redesign Lab rats’ memory affected by mobile phones More orgasms for women with wealthy partners Websites out to find perfect match of debt to debt-collector Conficker worm: worst is yet to come Opinion Dealing the gay card David Cohen 6 Iran election: The biggest loser is Western media credibility Nevil Gibson 5 More Opinion Sponsored Links For expert budget analysis click on Grant Thornton. SAVE TIME and MONEY on your foreign exchange requirements with Currency Online . Get a 3 Month Term Deposit at 4.30% with RaboPlus, NZ’s safest bank . NZ Market Snapshot var so = new SWFObject("/files/flash/widget_v3.swf", "Data Tabs", "300", "148", "8", "#FFFFFF"); so.write("flashwidgetholder"); More market information » From the Horse's Mouth Red Hat Enterprise Virtualization Beta Draws Industry Interest Networking - Efficient Marketing on a small budget Ericsson sole supplier of HSPA network non-binding referendum waste of time and money CARE CHEMIST AND LPL GROUP CELEBRATE Latest Wellington Travelodge shows off $11m upgrade Little change in revenue for councils Recession prompts saving - English NZ power production plummets Renewable energy sources power NZ Vodafone strikes bundling deal with Sky TV as Telecom tie-up withers Living Cell buoyed by diabetes trials Air NZ passenger numbers down 10 percent One in four jobless finding work within six months NZ sharemarket eases in early trading NBR Services Email alerts NBR mobile RSS SUBSCRIBE: Print edition Digital replica Living Cell buoyed by diabetes trials NZPA | Wednesday June 17 2009 - 11:48am Auckland-based biotechnology company Living Cell Technologies is to open a $2.5 million high-tech pig breeding facility for up to 50 animals in Invercargill next month. The company said it was making "stunning" progress with human trials of its diabetes treatment, The New Zealand Herald reported today. The company was also working on a treatment for Parkinson's disease and there were about 2500 disorders that could be treated with animal cell therapy, Living Cell Technologies founding director David Collinson said. The company needed to build 80 pig facilities during the next few years to meet the market demand, which would be enough to treat 30,000 to 40,000 people a year. Living Cell Technologies in October was granted permission, subject to a review, by the former Labour-led government to restart human trials on pig cell transplants halted in New Zealand in 1997. Mr Collinson said the review of safety issues had been signed off but the company was waiting for a decision from Health Minister Tony Ryall. The company expected to spend about $2.5 billion during the next 10 years, with funding sources including pharmaceutical companies, institutional investors, Government and income. Mr Ryall said the Government was following a legal process which had been agreed by the previous government and the company. Print this page Share or email this article Post new comment Your name: The information entered here will appear with your comment. Leaving this field blank will default to anonymous. Subject: Comment: * More information about formatting options Home Business Markets Politics Tech Property Opinion Ad/Media Well-being Private Bin Arts & Film Privacy Policy Copyright Information Sitemap Made by Sparks Interactive document.write(unescape("%3Cscript src='<a style="font-weight:normal" href="http://www.google-analytics.com/ga.js'">http://www.google-analytics.com/ga.js'</a> type='text/javascript'%3E%3C/script%3E")); var pageTracker = _gat._getTracker("UA-4030813-1");pageTracker._initData();pageTracker._trackPageview(); var _rsCI="nz-nbr"; var _rsCG="0"; var _rsDT=0; // to turn on whether to get the document title, 1=on var _rsDU=0; // to turn on or off the applet, 1=on var _rsDO=0; // to turn on debug output to the console, 1=on, only works if _rsDU=1 var _rsX6=0; // to force use of applet with XP and IE6, 1=on, only works if _rsDU=1 var _rsSI=escape(window.location); var _rsLP=location.protocol.indexOf('https')-1?'https:':'http:'; var _rsRP=escape(document.referrer); var _rsND=_rsLP+'//secure-nz.imrworldwide.com/'; if (parseInt(navigator.appVersion)=4) { var _rsRD=(new Date()).getTime(); var _rsSE=0; var _rsSV=""; var _rsSM=0; _rsCL=' '; } else { _rsCL=' '; } document.write(_rsCL);

Click here to visit inline page

Follow Ups:

Re: LCT buoyed by 'stunning progress' in human trials - Steve R 22:41:28 2009/06/16 (0)
Re: LCT to expand facilities - TVNZ 22:11:51 2009/06/16 (0)

Post a Followup

[ Follow Ups ] [ Post Followup ] [ The Islet Foundation Public Message Forum ]

Name:
E-Mail: (Optional)
Subject:
Comments:
Link URL: (Optional)
Link Title:
Image URL: (Optional)